Pfizer terminates pagoclone agreement with Indevus
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 25 (Table of Contents)
Published: 2 Jun-2002
DOI: 10.3833/pdr.v2002.i25.1046 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer handed back to Indevus Pharmaceuticals, the development and commercialization rights to pagoclone (Panex®), a partial GABA receptor agonist, in development for the treatment of anxiety disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS